Kleine Moleküle & Peptide

DOTA-Lanreotide acetate

Precursor for radiolabelled DOTA-Lanreotide

DOTA-BIM-23014; CA index name: L-Threoninamide, 3-(2-naphthalenyl)-N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2→7) disulfide

Sequence: DOTA-D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂, cyclic disulfide; DOTA = N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-; Supplied as acetate salt

Qualität

Research Chemical

Eigenschaften

Molare Masse 1481.7

CAS RN [213187-44-1] (net peptide)

Reinheit ≥ 95 %

  • Colorless to off-white freeze-dried solid

Zertifikate

CoA: appearance, MS (identity), HPLC (purity)

Literatur

Smith-Jones P.M. et al. DOTA-Lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999, 140, 5136 - 5148.

Banerjee S. et al. ¹⁷⁷Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nucl. Med. Biol. 2004, 31, 753–759.

Zur Anfrage hinzufügen

ProduktnummerFüllmengeAnzahl
Produktnummer: 9831Füllmenge: 1 mg
Produktnummer: 9831Füllmenge: 10 mg
Produktnummer: 9831
Produkt hinzugefügt